Related references
Note: Only part of the references are listed.Effect of treatment with 5-lipoxygenase inhibitor VIA-2291 (atreleuton) on coronary plaque progression: a serial CT angiography study
Suguru Matsumoto et al.
CLINICAL CARDIOLOGY (2017)
Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms
Charles N. Serhan
FASEB JOURNAL (2017)
Specialized pro-resolving mediators in cardiovascular diseases
Gabrielle Fredman et al.
MOLECULAR ASPECTS OF MEDICINE (2017)
Leukotriene-Receptor Antagonists Versus Placebo in the Treatment of Asthma in Adults and Adolescents A Systematic Review and Meta-analysis
Michael Miligkos et al.
ANNALS OF INTERNAL MEDICINE (2015)
HAMI 3379, A CYSLT2R ANTAGONIST, DOSE- AND TIME-DEPENDENTLY ATTENUATES BRAIN INJURY AND INHIBITS MICROGLIAL INFLAMMATION AFTER FOCAL CEREBRAL ISCHEMIA IN RATS
Q. J. Shi et al.
NEUROSCIENCE (2015)
Autocrine activity of cysteinyl leukotrienes in human vascular endothelial cells: Signaling through the CysLT2 receptor
Valerie Capra et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2015)
The protective role of montelukast against intestinal ischemia-reperfusion injury in rats
Shenbao Wu et al.
SCIENTIFIC REPORTS (2015)
Montelukast, a Cysteinyl Leukotriene Receptor-1 Antagonist Protects Against Hippocampal Injury Induced by Transient Global Cerebral Ischemia and Reperfusion in Rats
M. A. Saad et al.
NEUROCHEMICAL RESEARCH (2015)
Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7
Magnus Back et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
Montelukast prevents ischaemia/reperfusion-induced ovarian damage in rats
A. Akdemir et al.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2014)
Pro-resolving lipid mediators are leads for resolution physiology
Charles N. Serhan
NATURE (2014)
Effectiveness of montelukast administered as monotherapy or in combination with inhaled corticosteroid in pediatric patients with uncontrolled asthma: a prospective cohort study
Denis Berube et al.
ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY (2014)
Effects of montelukast on the healing of ischemic colon anastomoses
Atilla Celik et al.
AMERICAN JOURNAL OF SURGERY (2013)
Efficacy of iloprost and montelukast combination on spinal cord ischemia/reperfusion injury in a rat model
Gokhan Lafci et al.
JOURNAL OF CARDIOTHORACIC SURGERY (2013)
Eicosanoids and Their Drugs in Cardiovascular Diseases: Focus on Atherosclerosis and Stroke
Valerie Capra et al.
MEDICINAL RESEARCH REVIEWS (2013)
Cysteinyl leukotrienes regulate endothelial cell inflammatory and proliferative signals through CysLT2 and CysLT1 receptors
Ernest Duah et al.
SCIENTIFIC REPORTS (2013)
HAMI 3379, a CysLT2 Receptor Antagonist, Attenuates Ischemia-Like Neuronal Injury by Inhibiting Microglial Activation
Xia-Yan Zhang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
Adult Asthma and Risk of Coronary Heart Disease, Cerebrovascular Disease, and Heart Failure: A Prospective Study of 2 Matched Cohorts
Carlos Iribarren et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2012)
Intracerebroventricular injection of HAMI 3379, a selective cysteinyl leukotriene receptor 2 antagonist, protects against acute brain injury after focal cerebral ischemia in rats
Qiao-Juan Shi et al.
BRAIN RESEARCH (2012)
Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease
Erik Ingelsson et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
The Efficacy and Tolerability of Intravenous Montelukast in Acute Asthma Exacerbations in Japanese Patients
Mitsuru Adachi et al.
JOURNAL OF ASTHMA (2012)
Cysteinyl leukotriene signaling through perinuclear CysLT1 receptors on vascular smooth muscle cells transduces nuclear calcium signaling and alterations of gene expression
Alison Eaton et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2012)
Transforming growth factor β1-induced astrocyte migration is mediated in part by activating 5-lipoxygenase and cysteinyl leukotriene receptor 1
Xue-Qin Huang et al.
JOURNAL OF NEUROINFLAMMATION (2012)
Cysteinyl leukotriene receptor antagonism alleviates renal injury induced by ischemia-reperfusion in rats
Hanan H. Hagar et al.
JOURNAL OF SURGICAL RESEARCH (2012)
Ameliorative potential of montelukast on ischemia-reperfusion injury induced vasculitic neuropathic pain in rat
Arunachalam Muthuraman et al.
LIFE SCIENCES (2012)
Cysteinyl Leukotriene Signaling Aggravates Myocardial Hypoxia in Experimental Atherosclerotic Heart Disease
Elena Nobili et al.
PLOS ONE (2012)
Lipoxygenase and Leukotriene Pathways: Biochemistry, Biology, and Roles in Disease
Jesper Z. Haeggstrom et al.
CHEMICAL REVIEWS (2011)
Upregulation of the 5-Lipoxygenase Pathway in Human Aortic Valves Correlates With Severity of Stenosis and Leads to Leukotriene-Induced Effects on Valvular Myofibroblasts
Edit Nagy et al.
CIRCULATION (2011)
Montelukast for the treatment of asthma in the adult population
Salima Amlani et al.
EXPERT OPINION ON PHARMACOTHERAPY (2011)
Synthesis of cysteinyl leukotrienes in human endothelial cells: subcellular localization and autocrine signaling through the CysLT2 receptor
Chiara Carnini et al.
FASEB JOURNAL (2011)
Protective effects of montelukast on ischemia-reperfusion injury in rat ovaries subjected to torsion and detorsion: biochemical and histopathologic evaluation
Akgun Oral et al.
FERTILITY AND STERILITY (2011)
Effect of combination of zafirlukast and quercetin on baroreflex sensitivity and endothelin production in rats with myocardial infarction
T. Kezeli et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Pranlukast Attenuates Hydrogen Peroxide-induced Necrosis in Endothelial Cells by Inhibiting Oxygen Reactive Species-mediated Collapse of Mitochondrial Membrane Potential
Rui Zhao et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2011)
Inhibition of leukotriene C4 action reduces oxidative stress and apoptosis in cardiomyocytes and impedes remodeling after myocardial injury
Ulrich M. Becher et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2011)
A Selective Cysteinyl Leukotriene Receptor 2 Antagonist Blocks Myocardial Ischemia/Reperfusion Injury and Vascular Permeability in Mice
Nathan C. Ni et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Montelukast, a cysteinyl leukotriene receptor-1 antagonist, attenuates chronic brain injury after focal cerebral ischaemia in mice and rats
Rui Zhao et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2011)
CYSTEINYL LEUKOTRIENE RECEPTOR 2 IS SPATIOTEMPORALLY INVOLVED IN NEURON INJURY, ASTROCYTOSIS AND MICROGLIOSIS AFTER FOCAL CEREBRAL ISCHEMA IN RATS
C. Z. Zhao et al.
NEUROSCIENCE (2011)
Leukotriene Antagonists as First-Line or Add-on Asthma-Controller Therapy
David Price et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
International Union of Basic and Clinical Pharmacology. LXXXIV: Leukotriene Receptor Nomenclature, Distribution, and Pathophysiological Functions
Magnus Back et al.
PHARMACOLOGICAL REVIEWS (2011)
Montelukast in asthma: a review of its efficacy and place in therapy
Pierluigi Paggiaro et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2011)
Resolvin E1 Regulates Adenosine Diphosphate Activation of Human Platelets
Gabrielle Fredman et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2010)
Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT2) receptor
F. Wunder et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease
Daniel Poeckel et al.
CARDIOVASCULAR RESEARCH (2010)
Treatment With 5-Lipoxygenase Inhibitor VIA-2291 (Atreleuton) in Patients With Recent Acute Coronary Syndrome
Jean-Claude Tardif et al.
CIRCULATION-CARDIOVASCULAR IMAGING (2010)
Montelukast protects against testes ischemia/reperfusion injury in rats
Hulya Ozturk et al.
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL (2010)
Leukotrienes and Atherosclerosis
Graziano Riccioni et al.
CURRENT DRUG TARGETS (2010)
Sulfido-peptide leukotrienes in coronary heart disease - relationship with disease instability and myocardial ischaemia
R. De Caterina et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2010)
Cysteinyl-leukotriene receptor antagonism blunts the acute hypotensive response to endotoxin in cats
Amy E. DeClue et al.
JOURNAL OF FELINE MEDICINE AND SURGERY (2010)
Protective Potential of Montelukast Against Hepatic Ischemia/Reperfusion Injury in Rats
Erkan Oezkan et al.
JOURNAL OF SURGICAL RESEARCH (2010)
Montelukast in guidelines and beyond
Jean Bousquet et al.
ADVANCES IN THERAPY (2009)
Genetic and pharmacological inhibition of the 5-lipoxygenase/leukotriene pathway in atherosclerotic lesion development in ApoE deficient mice
Richard Yang Cao et al.
ATHEROSCLEROSIS (2009)
Anti-atherogenic effects of montelukast associated with reduced MCP-1 expression in a rabbit carotid balloon injury model
Song Ge et al.
ATHEROSCLEROSIS (2009)
Cysteinyl-leukotriene receptor antagonist montelukast decreases blood-brain barrier permeability but does not prevent oedema formation in traumatic brain injury
Necat Biber et al.
BRAIN INJURY (2009)
Leukotriene Signaling in Atherosclerosis and Ischemia
Magnus Back
CARDIOVASCULAR DRUGS AND THERAPY (2009)
Montelukast Inhibits Matrix Metalloproteinases Expression in Atherosclerotic Rabbits
Dezhi Liu et al.
CARDIOVASCULAR DRUGS AND THERAPY (2009)
Inhibitors of the 5-Lipoxygenase Pathway in Atherosclerosis
Magnus Back
CURRENT PHARMACEUTICAL DESIGN (2009)
Pranlukast Attenuates Ischemia-like Injury in Endothelial Cells Via Inhibiting Reactive Oxygen Species Production and Nuclear Factor-kappa B Activation
San-Hua Fang et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2009)
A Novel Peptide Agonist of Formyl-Peptide Receptor-Like 1 (ALX) Displays Anti-Inflammatory and Cardioprotective Effects
Iris Hecht et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Effect of Montelukast and MK-886 on Hepatic Ischemia-Reperfusion Injury in Rats
Gul Daglar et al.
JOURNAL OF SURGICAL RESEARCH (2009)
Safety and Tolerability of Montelukast in Placebo-Controlled Pediatric Studies and Their Open-Label Extensions
Hans Bisgaard et al.
PEDIATRIC PULMONOLOGY (2009)
Multidrug resistance protein-1 affects oxidative stress, endothelial dysfunction, and atherogenesis via leukotriene C4 export
Cornelius F. H. Mueller et al.
CIRCULATION (2008)
Montelukast inhibits tumour necrosis factor-α-mediated interleukin-8 expression through inhibition of nuclear factor-κB p65-associated histone acetyltransferase activity
F. Tahan et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2008)
Leukotriene modifiers in the treatment of cardiovascular diseases
Graziano Riccioni et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2008)
Activation of CysLT receptors induces astrocyte proliferation and death after oxygen-glucose deprivation
Xiao-Jia Huang et al.
GLIA (2008)
The potential link between atherosclerosis and the 5-lipoxygenase pathway:: investigational agents with new implications for the cardiovascular field
Carl Whatling et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2007)
Role of cysteinyl leukotrienes in the proliferation and the migration of murine vascular smooth muscle cells in vivo and in vitro
Yasuhiro Kaetsu et al.
CARDIOVASCULAR RESEARCH (2007)
Role of 5-lipoxygenase in myocardial ischemia-reperfusion injury in mice
Anna Adamek et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2007)
The effect of montelukast and low-dose theophylline on cardiovascular disease risk factors in asthmatics
Hooman Allayee et al.
CHEST (2007)
Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: Critical update and emerging trends
Valerie Capra et al.
MEDICINAL RESEARCH REVIEWS (2007)
Montelukast reduces ischaemia/reperfusion-induced bladder dysfunction and oxidant damage in the rat
Goksel Sener et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2007)
Spatio-temporal expression of cysteinyl leukotriene receptor-2 mRNA in rat brain after focal cerebral ischemia
San-Hua Fang et al.
NEUROSCIENCE LETTERS (2007)
Leukotriene receptors:: Crucial components in vascular inflammation
Magnus Back
THESCIENTIFICWORLDJOURNAL (2007)
Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis
Cristina Vidal et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Treatment of inflammatory diseases by selective eicosanoid inhibition: a double-edged sword?
Saul Yedgar et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2007)
Leukotriene D4 induces brain edema and enhances CysLT2 receptor-mediated aquaporin 4 expression
Meng-Ling Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Pranlukast, a cysteinyl leukotriene receptor 1 antagonist, protects mice against brain cold injury
Xiao-Dong Qian et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2006)
Efficacy and safety of montelukast in adults with asthma and allergic rhinitis
J. Chr. Virchow et al.
RESPIRATORY MEDICINE (2006)
Distinct roles of CysLT1 and CysLT2 receptors in oxygen glucose deprivation-induced PC12 cell death
Wen-Wen Sheng et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Montelukast protects against renal ischemia/reperfusion injury in rats
Goksel Sener et al.
PHARMACOLOGICAL RESEARCH (2006)
Montelukast prevents the decrease of interleukin-10 and inhibits NF-κB activation in inflammatory airway of asthmatic guinea pigs
Yuqing Wu et al.
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY (2006)
Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice
J Jawien et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2006)
Increased expression of cysteinyl leukotriene receptor-1 in the brain mediates neuronal damage and astrogliosis after focal cerebral ischemia in rats
S. H. Fang et al.
NEUROSCIENCE (2006)
Cysteinyl-leukotriene receptor antagonists: Present situation and future opportunities
V. Capra et al.
CURRENT MEDICINAL CHEMISTRY (2006)
Amelioration of sepsis-induced hepatic and ileal injury in rats by the leukotriene receptor blocker montelukast
G Sener et al.
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS (2005)
Effects of montelukast treatment on clinical and inflammatory variables in patients with cystic fibrosis
I Stelmach et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2005)
Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells
V Nascimento-Silva et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2005)
Leukotriene modifiers as potential therapeutics for cardiovascular disease
CD Funk
NATURE REVIEWS DRUG DISCOVERY (2005)
Effect of montelukast on nuclear factor κB activation and proinflammatory molecules
S Maeba et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2005)
Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction - A randomized trial
H Hakonarson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Short-term effects of montelukast in stable patients with moderate to severe COPD
P Celik et al.
RESPIRATORY MEDICINE (2005)
The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke
A Helgadottir et al.
NATURE GENETICS (2004)
Long-term montelukast therapy in moderate to severe COPD - a preliminary observation
I Rubinstein et al.
RESPIRATORY MEDICINE (2004)
The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm
L Zhao et al.
NATURE MEDICINE (2004)
Cysteinyl leukotrienes and their receptors: (Cellular distribution and function in immune and inflammatory responses
Y Kanaoka et al.
JOURNAL OF IMMUNOLOGY (2004)
Molecular and functional aspects of human cysteinyl leukotriene receptors
V Capra
PHARMACOLOGICAL RESEARCH (2004)
Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis
JH Dwyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis
R Spanbroek et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Benefit-risk assessment of antileukotrienes in the management of asthma
L Garcia-Marcos et al.
DRUG SAFETY (2003)
Anti-inflammatory effects of montelukast in mild cystic fibrosis
S Schmitt-Grohé et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2002)
Bronchoprotective effects of leukotriene receptor antagonists in asthma - A meta-analysis
GP Currie et al.
CHEST (2002)
Targeted gene disruption reveals the role of cysteinyl leukotriene 1 receptor in the enhanced vascular permeability of mice undergoing acute inflammatory responses
A Maekawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall
AS Nayak et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2002)
Novel lipid mediator regulators of endothelial cell proliferation and migration:: Aspirin-triggered-15R-lipoxin A4 and lipoxin A4
IM Fierro et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Emerging role of antileukotriene therapy in allergic rhinitis
BJ Lipworth
CLINICAL AND EXPERIMENTAL ALLERGY (2001)
Production of leukotrienes in a model of focal cerebral ischaemia in the rat
P Ciceri et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma
SS Salvi et al.
CHEST (2001)
Leukotriene B4:: Metabolism and signal transduction
T Yokomizo et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2001)
Leukotrienes as mediators of asthma
S Nicosia et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2001)
Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial
EO Meltzer et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2000)
Comparison of the effects of intravenous and oral montelukast on airway function: a double blind, placebo controlled, three period, crossover study in asthmatic patients
RJ Dockhorn et al.
THORAX (2000)
Monoclonal anti-CD18 antibody prevents transcellular biosynthesis of cysteinyl leukotrienes in vitro and in vivo and protects against leukotriene-dependent increase in coronary vascular resistance and myocardial stiffness
A Sala et al.
CIRCULATION (2000)
Leukotrienes in caudiovascular diseases
G Folco et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2000)
Lipoxygenase inhibitor FLM 5011, an effective protectant of myocardial microvessels against ischemia-reperfusion injury? An ultrastructural-morphometric study
K Welt et al.
EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY (2000)
Share Paper
